Long-Term Effects of Allergy Shots: 7-12 Year Durability and No Documented Harms
Long-term effects of allergy shots fall into two categories: durability (7-12+ years of post-course remission documented by Durham SR et al, NEJM 1999;341:468-475; 10-year asthma prevention in children per Jacobsen PAT Allergy 2007) and safety (no documented cumulative organ toxicity or long-term harm from completed courses). The 0.1-0.2% per-injection systemic reaction risk per Epstein 2013/2014 applies only DURING treatment. Some patients relapse 25-40% over 5 years post-discontinuation.
7 peer-reviewed sources
After a completed 3-5 year SCIT course, benefits persist 7-12+ years in responders (Durham 1999 NEJM). No long-term organ toxicity or cumulative harms are documented. The per-injection systemic reaction risk ends when injections stop.
The essentials
When patients ask about long-term effects of allergy shots, the question contains two distinct clinical meanings that must be addressed separately: durability (do the benefits persist after treatment ends?) and safety (does completing a multi-year injection course cause any lasting harm?).
The honest answers are: durability is excellent and well-documented; long-term harm is not documented in the published literature.
Before committing to a 3-5 year immunotherapy course, confirming your sensitization profile is essential to determining whether the long-term durability data applies to your specific allergen exposure pattern. Curex offers at-home IgE testing covering 40+ allergens with results in about a week, giving your allergist the sensitization data needed to identify which long-term outcomes are most relevant to your case.
DURASBILITY: The landmark evidence is Durham SR et al, NEJM 1999;341:468-475. In this trial, patients who completed 3-4 years of grass SCIT were randomized to either continue or discontinue. The discontinuation group maintained clinical remission comparable to the continued-treatment group for at least 3 further years of follow-up — with persistent immunologic changes (allergen-specific IgG4, reduced IgE responses). This is the foundational evidence that SCIT is disease-modifying, not merely suppressive. Longer-term observational data from the Durham cohort describe continued benefit 7-12+ years post-course in responders.
The Jacobsen PAT study (Allergy 2007;62:943-948) added pediatric asthma prevention to the long-term benefit picture: children who received 3 years of grass and/or birch SCIT were followed for 10 years. At 10-year follow-up, the odds ratio for remaining asthma-free was 4.6 (95% CI 1.5-13.7) favoring SCIT. The original PAT trial (Möller C et al, JACI 2002) documented fewer new asthma diagnoses at 3-year follow-up. This preventive effect persisted approximately 7 years after treatment ended — establishing that early SCIT in allergic children can alter the natural history of allergic disease.
SAFETY: No long-term cumulative organ toxicity, immunologic dysfunction, or chronic harm from completed SCIT courses is documented in the published literature. The 0.1-0.2% per-injection systemic reaction rate (Bernstein DI et al, JACI 2008; Epstein TG et al, Ann Allergy Asthma Immunol 2013 PMID 23535092; 2014 PMID 24607043) is a treatment-period risk that ends when injections stop. There is no ongoing reaction risk after course completion.
The honest other side of long-term effects: 25-40% of patients relapse over 5 years post-discontinuation, based on multi-trial observational patterns reviewed in Cox and Cohn, Ann Allergy Asthma Immunol 2007. Relapse rates vary by allergen — grass pollen tends to have lower relapse; dust mite can approach 55%. This is incomplete restoration of pre-treatment severity, not a rebound or worsening beyond baseline. Patients who relapse can usually be re-initiated with an abbreviated build-up per Cox 2011 PP3.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
The long-term effects timeline extends well beyond the treatment course itself. Understanding what happens to benefit after the 3-5 year course ends is the primary content of this page.
Dose escalation phase. No durable benefit established at this stage — Cox 2011 PP3 states patients should not expect significant clinical benefit during build-up. Dropout here forfeits any long-term durability.
Maximum benefit accumulates in years 2-3. IgG4 blocking antibodies and T-regulatory cell expansion are established. Only 43.9% of initiated patients reach this phase per Tkacz 2021 (n=103,207). Completing this phase is required for long-term durability.
Durham SR et al, NEJM 1999;341:468-475: 7-12+ years durable remission after a completed 3-year course. PAT study: 10-year asthma prevention in children. 25-40% relapse over 5 years. Re-initiation with abbreviated build-up is possible for relapsers per Cox 2011 PP3.
Efficacy by allergen — what the data shows
Long-term efficacy is best understood allergen-by-allergen, as durability varies. The grass SCIT evidence is the most robust for long-term remission.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
Patients weighing the long-term commitment of SCIT against alternatives need to understand which options deliver lasting disease modification vs. symptomatic suppression only.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
Allergy Shots (SCIT) | |||||
Sublingual Drops (SLIT) | |||||
Antihistamines (daily) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
Curex delivers that same disease-modifying immunotherapy as an at-home allergy shot: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist and self-administered as one weekly shot at home for $129/month. The mechanism is identical to clinic SCIT — T-regulatory cell induction and IgG4 blocking antibodies driving the same 3-5 year immunologic reprogramming — while your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand, making durable, well-tolerated maintenance possible for eligible patients without weekly clinic trips.
See if at-home shots are right for youSide effects — what to watch for
Long-term safety of allergy shots is defined by what is NOT present in the literature: no documented cumulative tissue damage, organ toxicity, or immunologic dysfunction from completed SCIT courses. The reaction risk during treatment is the relevant safety consideration, not post-treatment effects.
Frequently asked questions
How long do allergy shots last after you stop?
After completing a 3-4 year SCIT course, Durham SR et al (NEJM 1999;341:468-475) demonstrated clinical remission maintained for at least 3 further years post-discontinuation — comparable to patients who continued treatment. Observational follow-up from the Durham cohort describes continued benefit 7-12+ years post-course in responders. However, relapse does occur: rates range from roughly 0% to 55% depending on allergen type, with grass pollen at the lower end and dust mite at the higher end per Cox and Cohn (Ann Allergy Asthma Immunol 2007). The honest summary: most patients who complete a full course have years of benefit after stopping, but not all patients maintain full benefit indefinitely.
Do allergy shots have any long-term side effects?
No long-term side effects, cumulative organ toxicity, or chronic immunologic dysfunction from completed SCIT courses are documented in the published literature. The adverse effects associated with allergy shots — local injection-site reactions (78.3% of patients per LOCAL study) and systemic reactions (0.1-0.2% per injection per Epstein 2014) — are treatment-period risks that apply only during active injections. These risks end when injections stop. There is no ongoing per-injection reaction risk after course completion. The primary post-course risk is relapse of allergy symptoms (25-40% over 5 years), which is not a side effect but an incomplete restoration of pre-treatment severity.
Can allergy shots prevent asthma long-term?
Yes, this is one of the most compelling long-term benefits for pediatric patients. The Prevention of Allergy and Asthma in Children (PAT) study (Jacobsen L et al, Allergy 2007;62:943-948) followed children given 3 years of grass and/or birch SCIT for 10 years. The odds ratio for remaining asthma-free at 10-year follow-up was 4.6 (95% CI 1.5-13.7) favoring SCIT. The original PAT trial (Möller C et al, JACI 2002) showed fewer new asthma diagnoses at 3-year mark. This preventive effect persisted approximately 7 years after treatment ended. These findings support the disease-modifying (not merely suppressive) nature of SCIT: early treatment can alter the natural history of allergic disease, not just treat symptoms.
What happens to my immune system years after allergy shots?
Completed SCIT courses produce lasting immunologic changes that underlie the long-term clinical benefit. Documented persistent changes include: increased allergen-specific IgG4 blocking antibodies, reduced basophil and mast cell sensitivity to the treated allergen, reduced allergen-specific IgE over time, and persistent T-regulatory cell activity that suppresses Th2-mediated allergic responses. Durham SR et al (NEJM 1999) documented these immunologic changes persisting in the discontinuation group alongside maintained clinical remission. These are not harmful changes — they represent the immune tolerance the treatment was designed to induce. No adverse immunologic rebound, autoimmune activation, or global immune suppression has been documented in long-term SCIT follow-up.
Is it safe to do allergy shots for 5 years?
Yes. The standard SCIT course of 3-5 years per Cox 2011 PP3 is the treatment protocol associated with the best durability outcomes (Durham 1999 NEJM). There is no evidence that 5 years of allergy shots produces cumulative harm compared to 3 years. The per-injection systemic reaction risk (0.1-0.2% per visit) is a constant throughout treatment — it does not increase with longer courses. Some patients continue beyond 5 years if their symptom control is still benefiting from ongoing maintenance; this decision is individualized per Cox 2011 PP3. Venom immunotherapy for honeybee allergy is often continued for longer (5+ years) due to higher relapse risk after shorter courses, with no documented cumulative harm.
What are the benefits of allergy shots 10 years later?
Evidence for long-term benefit 10 years post-treatment comes primarily from two sources: the Durham 1999 NEJM grass SCIT cohort (7-12+ years remission in responders) and the PAT study 10-year follow-up (Jacobsen 2007), which showed sustained asthma prevention benefit in children treated as adolescents. For adult patients who completed SCIT for perennial allergens (dust mite, pet dander), the evidence is somewhat less robust — dust mite SCIT has higher relapse rates. The Cochrane meta-analysis (Calderón 2007) documents the during-treatment efficacy, and the Durham/PAT data frame what happens after. For patients who respond well and complete the full course, 10-year durability is biologically supported but varies by allergen and individual response.
If I relapse after allergy shots, can I start over?
Yes. Cox 2011 PP3 describes a re-initiation protocol for patients who relapse after completing a course and then discontinuing. Re-initiation typically uses a shorter build-up than the original course — some patients tolerate a faster escalation than their initial treatment because residual immunologic tolerance allows higher starting doses. The re-initiation decision should be made with your allergist, who will reassess your current sensitization pattern (which may have changed since your original treatment) and design an extract accordingly. The re-initiation benefit-risk calculation is generally favorable, particularly for patients with documented high relapse-rate allergens (dust mite, mold) who had clear benefit during their original course.
Do allergy shots reduce the chance of getting new allergies?
Some evidence suggests completed SCIT courses reduce the development of new allergic sensitizations. The PAT study (Jacobsen 2007) showed not only reduced asthma incidence but also reduced development of new sensitizations in treated children at 10-year follow-up, though this was a secondary finding rather than the primary endpoint. The mechanism — shifting the immune system toward Th1 and T-regulatory responses and away from the Th2 dominance that drives new sensitization — is biologically plausible. However, this benefit is less robustly quantified across diverse populations and allergens than the symptom remission and asthma prevention data. Current clinical guidance does not list sensitization prevention as a primary indication for SCIT, though it is considered a potential secondary benefit.
Related Articles
One-Time Allergy Shot: Steroids vs. SCIT | Curex
SCIT is never a one-time procedure. Learn what 'one-time allergy shot' actually means — Kenalog, Depo-Medrol, Xolair, or epinephrine — and why none modify disease.
Read moreSymptoms of Allergy Shots | Curex Allergy Shot Guide
Symptoms of allergy shots span three tiers: local (78.3%), large local (0.4%), and systemic grade 1–4 (0.1–0.2%). Fatigue and body aches are reported but unquantified in surveillance.
Read moreHeadache After Allergy Shot — Data Gap Explained | Curex
Headache after an allergy shot is patient-reported but not tracked in AAAAI surveillance. No prevalence number exists. Here is what is known and when headache is an emergency.
Read moreBody Aches After Allergy Shots | Curex Allergy Shot Guide
Body aches after allergy shots are anecdotally reported but have zero peer-reviewed prevalence data. Cytokine-plausible but unquantified. Aches plus spreading hives needs 911.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAre Allergy Shots Effective? | Curex Guide
Are allergy shots effective? Cochrane meta-analysis of 51 RCTs (n=2,871) found symptom SMD −0.73. Per-allergen rates: venom 95%+, grass 80%, cat 62%. Full evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.